Adherence to pharmacological treatment and specific immunotherapy in allergic rhinitis

Clinical and Experimental Allergy

Volumn 43, Issue 1, 2013, Pages 22-28

  Passalacqua, G ^a   Baiardini, I ^a   Senna, G ^b   Canonica, G W ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

Adherence; Allergic rhinitis; Compliance; Medication; Specific immunotherapy

Indexed keywords

ANTIHISTAMINIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; CROMOGLYCATE DISODIUM; LEUKOTRIENE RECEPTOR BLOCKING AGENT; STEROID;

ALLERGIC RHINITIS; ARTICLE; FOLLOW UP; HUMAN; IMMUNOTHERAPY; MEDICAL LITERATURE; PATIENT COMPLIANCE; PATIENT EDUCATION; PRIORITY JOURNAL; SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY;

HUMANS; IMMUNOTHERAPY; PATIENT COMPLIANCE; RHINITIS, ALLERGIC, PERENNIAL;

EID: 84871685736     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2012.04052.x     Document Type: Article

References (72)

1. Heynes RB, Taylor DW, Sackett DL, eds. Compliance in health care. Baltimore: John Hopkins University Press, 1979.
2. Haynes RB, Yao X, Degani A, Kripalani S, Garg A, McDonald HP. Interventions for enhancing medication adherence. Cochrane Database of Systematic Reviews. 2005 Oct 19; (4):CD000011.
3. Ostergberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353:487-97.
4. Cleemput I, Kesteloot K. Economic implications of non-compliance in health care. Lancet 2002; 359:2129-30.
5. Cleemput I, Kesteloot K, DeGeest SA. Review of the literature on the economics of noncompliance. Room for methodological improvement. Health Policy 2002; 59:65-94.
6. Richter A, Anton SE, Koch P, Dennett SL. The impact of reducing dose frequency on health outcomes. Clin Ther 2003; 25:2307-35.
7. Sabaté E, ed. Adherence to Long-Term Therapies: Evidence for Action. Geneva, Switzerland: World Health Organization, 2003.
8. Christensen AJ. Patient adherence to medical treatment regimens: bridging the gap between behavioral science and biomedicine. Current Perspectives In Psychology series. New Haven: Yale University Press, 2004.
9. Di Matteo M. Variations on patients' adherence to medical recommendations: a quantitative review of 50 years of research. Med Care 2004; 42:200-9.
10. Baiardini I, Braido F, Giardini A et al. Adherence to treatment: assessment of an unmet need in asthma. J Investig Allergol Clin Immunol 2006; 16:218-23.
11. Griffith S. A review of factors associated with compliance and the taking of prescribed medicines. Br J Gen Pract 1990; 40:114-6.
12. Baiardini I, Braido F, Bonini M, Compalati E, Canonica GW. Why do doctors and patients not follow guidelines? Curr Opin Allergy Clin Immunol 2009; 9:228-33.
13. Cadieux RJ. Antidepressant drug interactions in the elderly. Understanding the P-450 system is half the battle in reducing risks. Postgrad Med 1999; 106:231-2.
14. Christensen K, Doblhammer G, Rau R, Vaupel JW. Ageing populations: the challenges ahead. Lancet 2009; 374:1196-208.
15. The World Allergy Organization White Book on Allergy. Pawankar R, Canonica GW, Casale T, Lockey RF eds. World Allergy Organization, Milwaukee, Wisconsin, USA, 2011.
16. Asher MI, Montefort S, Björksten B et al. ISAAC Phase Three Study Group. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC phases one and three repeat multicountry cross-sectional surveys. Lancet 2006; 368:733-43.
17. Lamb CE, Ratner PH, Johnson CE et al. Economic impact of workplace productivity losses due to allergic rhinitis compared with select medical conditions in the United States from an employer's perspective. Curr Med Res Opin 2006; 22:1203-10.
18. Nathan RA. The burden of allergic rhinitis. Allergy Asthma Proc 2007; 28:3-9.
19. Shaaban R, Zureik M, Soussan D et al. Rhinitis and onset of asthma: a longitudinal population-based study. Lancet 2008; 372:1049-57.
20. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989; 261:3273-7.
21. O'Connor SL, Bender BG, Gavin-Devitt LA, Wamboldt MZ, Milgrom H. Measuring adherence with the Doser CT in children with asthma. J Asthma 2004; 41:663-70.
22. Feinstein AR. On white-coat effects and the electronic monitoring of compliance. Arch Intern Med 1990; 150:1377-8.
23. Steiner JF, Earnest MA. The language of medication-taking. Ann Intern Med 2000; 132:926-30.
24. Avorn J, Monette J, Lacour A et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA 1998; 279:1458-62.
25. Bousquet J, Khaltaev N, Cruz AA et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008; 63(Suppl. 86):8-160.
26. Kniest FM, Wolfs BJ, Vos H et al. Mechanisms and patient compliance of dust-mite avoidance regimens in dwellings of mite-allergic rhinitic patients. Clin Exp Allergy 1992; 22:681-9.
27. de Blay F, Fourgaut G, Hedelin G et al. Medical Indoor Environment Counselor (MIEC): role in compliance with advice on mite allergen avoidance and on mite allergen exposure. Allergy 2003; 58:27-33.
28. Mihrshahi S, Webb K, Almqvist C, Kemp AS; CAPS Team. Adherence to allergy prevention recommendations in children with a family history of asthma. Pediatr Allergy Immunol. 2008; 19: 355-62.
29. Joseph KE, Adams CD, Cottrell L, Hogan MB, Wilson NW. Providing dust mite-proof covers improves adherence to dust mite control measures in children with mite allergy and asthma. Ann Allergy Asthma Immunol 2003; 90:550-3.
30. Bousquet J, Schünemann HJ, Zuberbier T et al. Development and implementation of guidelines in allergic rhinitis - an ARIA-GA2LEN paper. Allergy 2010; 65:1212-21.
31. Church MK, Watelet JB; Belgian SIGMA Group. Treating allergic rhinitis: continuous versus on-demand regime? Executive summary of the Supportive Initiatives for the Global Management of Allergy (SIGMA): report from the Belgian Working Group B-ENT 2009; 5(Suppl. 12):1-25.
32. Laekeman G, Simoens S, Buffels J et al. Continuous versus on-demand pharmacotherapy of allergic rhinitis: evidence and practice. Respir Med 2010; 104:615-25.
33. Valero A, de la Torre F, Castillo JA et al. Safety of rupatadine administered over a period of 1 year in the treatment of persistent allergic rhinitis: a mutlicentre, open-label study in Spain. Drug Saf 2009; 32:33-42.
34. Demoly P, Allaert FA, Lecasble M, Klossek JM; Groupe Pragma ERAP. a pharmaco-epidemiologic survey on perennial allergic rhinitis in every day medical practice in France. Presse Med 2003; 32:1066-73.
35. Mahadevia PJ, Shah S, Leibman C, Kleinman L, O'Dowd L. Patient preferences for sensory attributes of intranasal corticosteroids and willingness to adhere to prescribed therapy for allergic rhinitis: a conjoint analysis. Ann Allergy Asthma Immunol 2004; 93:345-50.
36. Stokes M, Amorosi SL, Thompson D, Dupclay L, Garcia J, Georges G. Evaluation of patients' preferences for triamcinolone acetonide aqueous, fluticasone propionate, and mometasone furoate nasal sprays in patients with allergic rhinitis. Otolaryngol Head Neck Surg 2004; 131:225-31.
37. Shah SR, Miller C, Pethick N, Uryniak T, Jones MK, O'Dowd L. Multicenter, randomized, single-blind, single-dose, crossover studies of specific sensory attributes of budesonide aqueous nasal spray and fluticasone propionate nasal spray. Clin Ther 2003; 8:2198-214.
38. Loh CY, Chao SS, Chan YH, Wang DY. A clinical survey on compliance in the treatment of rhinitis using nasal steroids. Allergy 2004; 59:1168-72.
39. Jeffe JS, Bhushan B, Schroeder JW Jr. Nasal saline irrigation in children: a study of compliance and tolerance. Int J Pediatr Otorhinolaryngol 2012; 76: 409-13.
40. Koberlein J, Kothe AC, Schaffert C. Determinants of patient compliance in allergic rhinoconjunctivitis. Curr Opin Allergy Clin Immunol 2011; 11:192-9.
41. Gani F, Pozzi E, Crivellaro MA et al. The role of patient training in the management of seasonal rhinitis and asthma: clinical implications. Allergy 2001; 56:65-8.
42. World Health Organization Position Paper. Allergen immunotherapy: therapeutical vaccines for allergic diseases. Bousquet J, Lockey R, Malling HJ, eds. Allergy 1998; 53 (suppl.): 1-33.
43. Canonica GW, Bousquet J, Casale T, Lockey RF, eds. Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy 2009; 64(Suppl. 91):1-59.
44. Joint Task Force on Practice Parameters; American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology. Allergen immunotherapy: a practice parameter second update. J Allergy Clin Immunol. 2007;120 (Suppl. 3): S25-85.
45. Möller C, Dreborg S, Ferdousi HA et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002; 109:251-6.
46. Novembre E, Galli E, Landi F et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 2004; 114:851-7.
47. Marogna M, Tomassetti D, Bernasconi M et al. Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study. Ann Allergy Asthma Immunol 2008; 101:206-11.
48. Lombardi C, Braga M, Incorvaia C, Senna G, Canonica GW, Passalacqua G. Administration regimens for sublingual immunotherapy. What do we know? Allergy 2009; 64:849-54.
49. Senna G, Ridolo E, Calderon M, Lombardi C, Canonica GW, Passalacqua G. Evidence of adherence to allergen-specific immunotherapy. Curr Opin Allergy Clin Immunol 2009; 9:544-8.
50. Lower T, Henry J, Mandik L, Janosky J, Friday GA Jr. Compliance with allergen immunotherapy. Ann Allergy 1993; 70:480-2.
51. Tinkelman D, Smith F, Cole WD , 3rd Slik HJ. Compliance with an allergen immunotherapy regimen. Ann Allergy Asthma Immunol 1995; 74:241-6.
52. Cohn JR, Pizzi A. Determinants of patient compliance with allergen immunotherapy. J Allergy Clin Immunol 1993; 91:734-7.
53. Ruiz FJ, Jimenez A, Cocoletzi J, Duran E. Compliance with and abandonment of immunotherapy. Rev Alerg Mex 1997; 44:42-4.
54. Rhodes BJ. Patient dropouts before completion of optimal dose, multiple allergen immunotherapy. Ann Allergy Asthma Immunol 1999; 82:281-6.
55. More DR, Hagan LL. Factors affecting compliance with allergy immunotherapy at a military medical center. Ann Allergy Asthma Immunol 2002; 88:391-4.
56. Pajno GB, Vita D, Caminiti L et al. Children's compliance with allergen immunotherapy according to administration routes. J Allergy Clin Immunol 2005; 116:1380-1.
57. Hankin CS, Cox L, Lang D et al. Allergy immunotherapy among Medicaid-enrolled children with allergic rhinitis: patterns of care, resource use, and costs. J Allergy Clin Immunol 2008; 121:227-32.
58. Lombardi C, Gani F, Landi M et al. Quantitative assessment of the adherence to sublingual immunotherapy. J Allergy Clin Immunol 2004; 113:1219-20.
59. Passalacqua G, Musarra A, Pecora S et al. Quantitative assessment of the compliance with once-daily sublingual immunotherapy regimen in real life (EASY project: evaluation of a novel SLIT formulation during a year). J Allergy Clin Immunol 2006; 117:946-8.
60. Passalacqua G, Musarra A, Pecora S et al. Quantitative assessment of the compliance with once-daily sublingual immunotherapy in children (EASY project: evaluation of a novel SLIT formulation during a year). Pediatr Allergy Immunol 2007; 18:58-62.
61. Roder E, Berger MY, de Groot H, ven Wijk RG. Sublingual immunotherapy in youngsters: adherence in a randomized clinical trial. Clin Exp Allergy 2008; 38:1669-767.
62. Marogna M, Spadolini I, Massolo A, Passalacqua G. Randomized controlled open study of SLIT for respiratory allergy in real life: clinical efficacy and more. Allergy 2004; 59:1205-10.
63. Senna G, Lombardi C, Canonica GW, Passalacqua G. How adherent to sublingual immunotherapy prescriptions are patients? The manufacturers' viewpoint. J Allergy Clin Immunol 2010; 126:668-9.
64. Passalacqua G, Frati F, Puccinelli P et al. Adherence to sublingual immunotherapy: the allergists' viewpoint. Allergy 2009; 64:1795-6.
65. Scurati S, Frati F, Passalacqua G, Puccinelli P, Hilaire C, Incorvaia C. Adherence issues related to sublingual immunotherapy as perceived by allergists. Patient Prefer Adherence. 2010; 4:141-5.
66. Vita D, Caminiti L, Ruggeri P, Pajno GB. Sublingual immunotherapy: adherence based on timing and monitoring control visits. Allergy 2010; 65:668-9.
67. Incorvaia C, Rapetti A, Scurati S, Puccinelli P, Capecce M, Frati F. Importance of patient's education in favouring compliance with sublingual immunotherapy. Allergy 2010; 65:1341-2.
68. Pajno GB, Caminiti L, Crisafulli G et al. Direct comparison between continuous and coseasonal regimen for sublingual immunotherapy in children with grass allergy: a randomized controlled study. Pediatr Allergy Immunol 2011; 22:803-7.
69. Bukstein D, Luskin AT, Farrar JR. The reality of adherence to rhinitis treatment: identifying and overcoming the barriers. Allergy Asthma Proc. 2011; 32:265-71.
70. Marple BF, Fornadley JA, Patel AA et al. American Academy of Otolaryngic Allergy Working Group on Allergic Rhinitis. Keys to successful management of patients with allergic rhinitis: focus on patient confidence, compliance, and satisfaction. Otolaryngol Head Neck Surg 2007; 136 (Suppl. 6):S107-24.
71. Simoens S, Laekeman G. Pharmacotherapy of allergic rhinitis: a pharmaco-economic approach. Allergy 2009; 64:85-95.
72. Carr WW, Nelson MR, Hadley JA. Managing rhinitis: Strategies for improved patient outcomes. Allergy Asthma Proc. 2008; 29:349-57.